highperformr logo

Avectas 's Overview

Total employees40
HeadquartersMaynooth
Founded2011

Avectas is a cell engineering technology company focused on revolutionizing the development of next-generation cell therapies. Its proprietary Solupore® platform enables the efficient, gentle, and scalable intracellular delivery of payloads (such as mRNA, DNA, proteins, and CRISPR-Cas9 RNP complexes) to primary cells for ex-vivo manufacturing. This technology aims to overcome the limitations of existing delivery methods, improving the efficacy, safety, and accessibility of advanced therapies for a range of diseases, including cancer and rare genetic disorders.

Where is Avectas 's Headquarters?

HQ Function

Global headquarters, research and development hub, strategic operations, and primary center for the innovation and advancement of Avectas's Solupore® cell engineering technology.

Notable Features:

State-of-the-art laboratory facilities within a modern business campus, designed to support cutting-edge research in cell and gene therapy.

Work Culture:

Avectas fosters a collaborative, innovative, and scientifically-driven work culture. Employees are focused on advancing cell therapy manufacturing and making a significant impact in biotechnology.

HQ Significance:

The Maynooth headquarters is central to Avectas's mission, housing its core R&D activities, intellectual property development, and global strategic management.

Values Reflected in HQ: The headquarters reflects Avectas's commitment to innovation, scientific excellence, and cutting-edge technology in the pursuit of transformative cell therapies.

Location:

Avectas operates with a global outlook, anchored by its headquarters and technology center in Maynooth, Ireland, a manufacturing and operations facility in Dublin, Ireland, and a strategic US office in Cambridge, Massachusetts. The company actively engages in international partnerships and collaborations to make its Solupore® technology available to cell therapy developers worldwide, supporting the advancement of innovative treatments across different geographies.

Street Address:

Unit 310, Maynooth Business Campus

City:

Maynooth

State/Province:

Co. Kildare

Country:

Ireland

Avectas 's Global Presence

Dublin, Ireland

Address: Unit 70, Block 71, The Plaza, Park West Business Park, Dublin 12, D12 N832, Ireland

Enhances Avectas's capacity for technology transfer, manufacturing scale-up, and operational support for European and global partners.

Cambridge, MA, USA

Address: 245 Main Street, Cambridge, MA 02142, USA

To drive growth and collaborations in the significant US cell and gene therapy market, fostering partnerships with pharmaceutical companies and research institutions.

Buying Intent Signals for Avectas

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Avectas

As of April 2025, Avectas ' leadership includes:

Michael Maguire, PhD - Chief Executive Officer
Robin Buckle, PhD - Chief Scientific Officer
Ann Brady - Chief Business Officer
Conor O’Donovan - Chief Financial Officer
Pasquale Sacco, PhD - VP, Head of Operations
Gillian Hendy - VP, Head of Business Development & Marketing
Justin Zylicz, PhD - VP, Head of Technology Development
Daniel O'Mahony - VP, Head of Engineering

Investors of Avectas

Avectas has been backed by several prominent investors over the years, including:

EQT Life Sciences
Seamus Mulligan
Act Venture Capital
Other Private Investors

Executive New Hires/Exits in the Last 12 Months

Hire4
Exits0

Avectas has significantly strengthened its leadership team over the past 12-15 months with several strategic vice president and C-level appointments to support its growth and development of the Solupore® platform. No major executive departures have been publicly announced during this period.

New Appointments:

Conor O’Donovan, Conor O’Donovan was appointed as Chief Financial Officer, bringing extensive financial leadership experience to Avectas.
Pasquale Sacco, PhD, Pasquale Sacco, PhD joined Avectas as VP, Head of Operations to lead and scale the company's operational and manufacturing capabilities.
Gillian Hendy, Gillian Hendy was appointed VP, Head of Business Development & Marketing to drive Avectas's commercial strategy and market expansion.
Daniel O'Mahony, Daniel O'Mahony joined as VP, Head of Engineering to lead engineering initiatives and technology development for the Solupore® platform.

Technology (Tech Stack) used by Avectas

Discover the tools Avectas uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Avectas Email Formats and Examples

Avectas primarily utilizes an email format consisting of the employee's first initial followed by their full last name, then '@avectas.com'. While this is the most commonly observed pattern, other formats may exist within the organization for specific roles or legacy reasons.

[first_initial][last]@avectas.com

Format

mmaguire@avectas.com

Example

85%

Success rate

News and media

Avectas Official WebsiteApril 10, 2024

Avectas Appoints Daniel O’Mahony as VP, Head of Engineering

Avectas announced the strategic appointment of Daniel O’Mahony to the position of VP, Head of Engineering. He will be responsible for leading the company's engineering strategy, including the design and development of Avectas’ proprietary Solupore® cell engineering platform....more

Avectas Official WebsiteMarch 6, 2024

Avectas Appoints Gillian Hendy as VP, Head of Business Development & Marketing

Avectas appointed Gillian Hendy as VP, Head of Business Development & Marketing. Gillian will lead Avectas’ business development and marketing strategy as the company advances its Solupore® non-viral cell engineering platform....more

EQT GroupMay 10, 2023

Avectas Secures EUR 30 Million in Financing Round Led by EQT Life Sciences

Avectas, a cell engineering company, announced the completion of a EUR 30 million (USD 33 million) financing. The round was led by EQT Life Sciences, investing from its LSP ELSM Manco III L.P. fund, and existing investor Seamus Mulligan also participated. The funds will be used to accelerate the clinical translation and commercialization of Avectas' Solupore® technology platform....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Avectas , are just a search away.